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a  b  s  t  r  a  c  t
Amorphous  solid  dispersions  (ASDs)  represent  a  promising  formulation  approach  for poorly  soluble
drugs.  We  explored  the  formulation-related  impact  of  ASDs  on permeation  rate,  apparent  solubility  and
molecular  solubility  of  the  poorly  soluble  drug  ABT-102.  The  inﬂuence  of  fasted  state  simulated  intestinal
ﬂuid  (FaSSIF)  as  dispersion  medium  was  also  studied.
ASDs  were  prepared  by hot-melt  extrusion.  Permeation  rate  was  assessed  by the  Caco-2  transwell
assay.  Cell  viability  and  barrier  integrity  were  assured  by AlamarBlue©,  TEER  and  permeability  of  the
hydrophilic  marker  carboxyﬂuorescein.  Apparent  solubility  and  molecular  solubility  were  evaluated  by
using  centrifugation  and  inverse  dialysis,  respectively.
The  in  vitro  permeation  rate  of ABT-102  from  aqueous  dispersions  of the ASD  was found  4  times
faster  than  that  from  the  dispersions  of the crystals,  while  apparent  solubility  and  molecular  solubility
of  ABT-102  were  increased.  Yet,  a further  increase  in apparent  solubility  due  to micellar  solubilization  as
observed  when  dispersing  the  ASD  in FaSSIF,  did  not  affect  molecular  solubility  or permeation  rate.
Overall,  a  good  correlation  between  permeation  rate  and  molecular  solubility  but not  apparent  solu-
bility  was  seen.
© 2012 Published by Elsevier B.V.
1. Introduction22
Increasingly, modern drug candidates tend to be poorly sol-23
uble. Many of them belong to class II of the Biopharmaceutical24
Classiﬁcation System (BCS), which predicts the intestinal absorp-25
tion of a given drug, based on its solubility and permeation across26
Caco-2 (Amidon et al., 1995). Class II comprises compounds of27
poor solubility but high permeability. Bioavailability of such BCS28
II compounds is restricted by their solubility. During the last years,29
various advanced oral formulation strategies have been used to30
enhance solubility and/or dissolution rate of poorly soluble active31
pharmaceutical ingredients (APIs), such as self (micro)emulsifying32
drug delivery systems (S(M)EDDS), microemulsions, nanocrys-33
tals, mesoporous silica and solid dispersions. It is controversially34
discussed, however, if and how these strategies enhance bioavail-35
ability (Singh et al., 2011).36
In a previous study, we investigated how the inclusion of the37
poorly soluble ABT-102 (TRPV1 antagonist (Kym et al., 2009))38
∗ Corresponding author at: FKF, SDU, Campusvej 55, 5230 Odense C, Denmark.
Tel.: +45 6550 2525; fax: +45 6615 8780.
E-mail address: mmb@ifk.sdu.dk (M. Brandl).
(chemical structure and characteristics (Frank et al., 2012)) into 39
taurocholate/phosphatidylcholine micelles, contained in simu- 40
lated intestinal ﬂuid, affects apparent solubility and permeation 41
rate across Caco-2 in the case of dispersions of the API. Fur- 42
thermore, a method was developed to determine the molecular 43
solubility in the presence of micelles. It was  seen that neither 44
the permeation rate nor the concentration of molecularly dis- 45
solved drug were increased in the presence of the micelles, even 46
though the micelles induced a remarkable increase in apparent 47
solubility. 48
In the present study we  focused on ASDs generated by hot 49
melt extrusion, which have been described to have a positive 50
effect on bioavailability of poorly soluble drugs (Breitenbach, 2002; 51
Leuner and Dressman, 2000; Vasconcelos et al., 2007). Typically, the 52
amorphous drug is imbedded in a polymer matrix (solid disper- 53
sion) or the drug is molecularly dispersed in the polymer matrix 54
(solid solution). Both systems contain the drug in its high energy 55
state (Brouwers et al., 2009; Janssens and Van den Mooter, 2009). 56
Typically, ASDs contain surfactants, which act as plasticizers and 57
crystallization inhibitors during production and in the solid state 58
of the ASDs. Furthermore, they serve as wetting agents, precipita- 59
tion inhibitors or solubilizing agents in the aqueous dispersions of 60
ASDs (Brouwers et al., 2009; Overhoff et al., 2008). 61
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Table  1
Composition of the extrudate formulation F1 and the corresponding placebo extru-
date (API-free formulation F1).
Ingredients F1 percentage [%] Placebo percentage [%]
ABT-102 5 –
Copovidon Typ K28
(Kollidon® VA 64)
81.5 85.7
Sucrose palmitate
(Surfhope® D-1615)
1.5 1.6
Poloxamer 188
(Pluronic® F68)
6.0 6.3
Polysorbate 80 (Tween
80®)
5.0 5.3
Fumed silica (Aerosil
200®)
1.0 1.1
The aim of the current study was to investigate an aqueous dis-62
persion of an ASD of the poorly soluble compound ABT-102 in terms63
of apparent and molecular solubility, as well as permeation rate.64
The ASD examined here consisted of the poorly soluble ABT-102, a65
hydrophilic polymer, and three surfactants.66
2. Materials and methods67
2.1. Materials68
ABT-102 (chemical structure and physicochemical properties69
published by Frank et al., 2012) as well as the ASDs (F1 and70
placebo extrudate; compositions: Table 1) were provided by Abbott71
GmbH & Co. KG (Ludwigshafen, Germany). A general descrip-72
tion of the preparation method is given by Breitenbach (2002).73
Hanks balanced buffered salt solution (washing and dispersion74
medium) and supplementary salts MgSO4·7H2O, NaHCO3 and75
CaCl2·2H2O (HBSS++) were obtained from Sigma–Aldrich Chemie76
GmbH (Munich, Germany). FaSSIF was prepared by dispersing SIF©77
instant powder (Phares Drug Delivery AG, Muttenz, Switzerland)78
containing taurocholate and lecithin (ratio 4:1) in the FaSSIF blank79
buffer.80
For cell culturing, Dulbecco’s modiﬁed Eagle’s medium (DMEM),81
supplemented with fetal bovine serum (FBS) and other additional82
ingredients (see Section 2.2.3) were utilized (all Biochrom AG,83
Berlin, Germany). Rat tail collagen was purchased from Roche84
Pharma AG (Mannheim, Germany). Bovine serum albumin (BSA),85
acetonitrile (ACN), Triton X-100, triﬂuoroacetic acid (TFA), NaOH,86
NaCl and NaH2PO4·H2O were obtained from Sigma–Aldrich Chemie87
GmbH.88
2.2. Methods89
2.2.1. Powder X-ray diffraction90
The ASD was investigated for crystalline parts of ABT-10291
using powder X-ray diffraction. Diffraction patterns were recorded92
using a Panalytical X’Pert Pro MPD  diffractometer (Panalytical, Ein-93
shoven, Netherlands) with a Pixel detector, Data Collector and High94
Score software. Measurements were performed with a Cu K radi-95
ation source at 40 kV voltage and 40 mA  current from 2.5◦ to 3.2◦96
2-theta in a continuous scanning mode. This range was chosen as97
the biggest reﬂex was seen to be at 2.9◦ 2-theta (supplementary98
data). The instrument was set to a step width of 0.006◦ 2-theta99
and a measurement time per step of 3000 s. The irradiated sample100
length was 20 mm.101
Sample preparation was done by milling approximately 1.5 g102
of ASD with a ball mill (Pulverisette 23, Fritsch, Idar-Oberstein,103
Germany) at 30 Hz for 30 s. A frontloading 35 mm diameter pow-104
der diffraction sample holder (Panalytical) was used for the105
measurements and the sample was covered with a Polyimide (Kap- 106
ton) ﬁlm (Chemplex, Palm City, FL, USA). 107
2.2.2. Preparation of dispersions 108
Sample dispersions were prepared by dispersing the ASDs 109
(beads) or crystalline ABT-102 in HBSS++ or FaSSIF in a volumetric 110
ﬂask (magnetic stirring at 400 rpm for 1 h at 37 ◦C). 111
2.2.3. Apparent solubility 112
Sample dispersions were prepared as described in Section 2.2.2. 113
Afterwards a deﬁned volume of the aqueous dispersions was 114
transferred into centrifugation tubes, which were centrifuged for 115
60 min at 18 500 × g at 37 ◦C (J2-MC, Beckman). These settings were 116
chosen, because the turbidity reached a plateau after 55 min  of cen- 117
trifugation at 18 500 × g i.e., all big particles are expected to be spun 118
down at that time point. After centrifugation, aliquots of the super- 119
natant were withdrawn, immediately diluted with acetonitrile and 120
analyzed via HPLC-UV/Vis, as described in Section 2.2.9. 121
The centrifugation approach was  found inappropriate for deter- 122
mination of the apparent solubility of the placebo extrudate plus 123
crystalline ABT-102 due to ﬂoating particles. Thus, for this sample, 124
separation of particles was performed by membrane ﬁltration (pore 125
size 0.2 m,  CA-membrane ﬁlter, Buch&Holm, Herlev, Denmark). 126
2.2.4. Quantiﬁcation of molecularly dissolved ABT-102 127
The method has been described by Frank et al. (2012). In brief, 128
the sample dispersion (prepared as described in Section 2.2.2) was 129
transferred into a beaker (donor; V = 200 ml). Then, Midi GeBAﬂex 130
dialysis tubes (3.5 kDa cut-off, Gene Bioapplication L.T.D., Yavne, 131
Israel) ﬁlled with 800 l of HBSS++ or FaSSiF blank buffer (both at 132
37 ◦C) (acceptor) were put into the sponge-like ﬂoating device and 133
set into the beaker. The beaker was  incubated in a shaking water 134
bath (Julabo SW23, Buch & Holm, Herlev, Denmark) at 37 ◦C and 135
50 rpm. Samples were drawn from inside the dialysis vials (accep- 136
tor) under equilibrium conditions, diluted with ACN and analyzed 137
as described in Section 2.2.9. Preliminary experiments indicated 138
that equilibrium was achieved after 20 h, and adsorptive drug-loss 139
was marginal (data not shown). 140
2.2.5. Caco-2 cell culture 141
DMEM,  supplemented with 10% FBS, 1% non-essential amino 142
acid, 1% penicillin-G, 1% streptomycin and 0.5% ciproﬂoxacin was 143
used as cell culture medium. Caco-2 cells (Rockville type) were sup- 144
plied with fresh medium every other day and passaged weekly. For 145
experiments, cells between passage numbers 46 and 75 were uti- 146
lized. Cells were seeded on pre-coated (rat tail collagen) 12-well 147
transwell or 96-well plates (Corning GmbH, Life Sciences, Wies- 148
baden, Germany) with a density of approximately 75 000/cm2 and 149
cultivated for 14–16 days at 37 ◦C in 5% CO2, until a conﬂuent mono- 150
layer was achieved. 151
2.2.6. Cytotoxicity 152
For evaluation of cytotoxicity, AlamarBlue© (Invitrogen, Carls- 153
bad, CA, USA), assay was  applied. Culture medium was removed, 154
cells were washed twice with HBSS++ and then sample dispersions 155
were added. After incubating for 3.5 h at 37 ◦C, the sample disper- 156
sions were discarded, cells were washed again with pre-warmed 157
HBSS++ and the testing reagent AlamarBlue© was added. Cells were 158
incubated for another 2 h and then ﬂuorescence was measured 159
using a ﬂuorescence plate reader (Fluoroscan Ascent, Labsystems 160
GmbH, Frankfurt, Germany). Fluorescence of sample treated cells 161
was expressed as a ratio relative to the negative control (HBSS++). 162
2.2.7. Barrier integrity 163
Culture medium was ﬁrst removed and then cells were washed 164
twice with HBSS++. Thereafter, inserts were set in the cellZscope® 165
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device (nanoAnalytics GmbH, Münster, Germany), HBSS++ was166
added apically and basolaterally. Next, transepithelial electri-167
cal resistance (TEER) was measured. After equilibration (approx.168
60 min), apical HBSS++ was replaced with sample dispersions and169
incubated for up to 3.5 h. Throughout the course of the incuba-170
tion, TEER of all 12 inserts was measured. In addition to the TEER171
measurements, carboxyﬂuorescein (CF) was added to the sample172
dispersions as hydrophilic marker (20 M)  and its permeability was173
evaluated. Samples were withdrawn at ﬁve time points from the174
basolateral side and the concentration of carboxyﬂuorescein (CF)175
in the acceptor was measured using a ﬂuorescence plate reader176
(Fluoroscan Ascent, Labsystems GmbH, Frankfurt, Germany).177
2.2.8. Permeation rate178
For evaluation of the permeation rate of ABT-102 across the cell179
monolayer, cells were treated as described in Section 2.2.5. BSA180
(c = 4%, w/w) was added to HBSS++ on the basolateral side to main-181
tain sink conditions and to saturate unspeciﬁc binding sites. This182
procedure has been described in the literature for performing per-183
meation rate studies with poorly soluble APIs (Buckley et al., 2012;184
Hubatsch et al., 2007).185
A three-fold volume of acetonitrile was added to the samples186
from the acceptor side to precipitate the protein. Next, samples187
were vortexed, followed by centrifugation for 10 min  at 10 000 rpm188
(CF 5415D, Eppendorf AG, Hamburg, Germany). Upon precipitation189
of BSA, the supernatant was immediately analyzed by HPLC–UV–vis190
(see Section 2.2.9).191
The normalized permeation rate (J) was calculated with the for-192
mula J = (1/A) × (dc/dt),  where A represents the surface area of the193
ﬁlter and dc/dt the permeation rate.194
2.2.9. Quantiﬁcation of ABT-102 by HPLC–UV–vis195
The instrument consisted of a separation unit (Ultimate196
3000, Dionex Co., Sunnyvale, USA) with a Dionex C18 column197
(4.6 mm × 300 mm)  coupled to an UV/Vis detector (Ultimate 3000,198
Dionex Co., Sunnyvale, USA). Measurements were performed at a199
ﬂow rate of 1.5 ml/min with a gradient, starting with 45% of eluent200
A (0.1% TFA in water) and 55% of eluent B (0.1%TFA in ACN), shift-201
ing to 20% of eluent A and 80% of eluent B over 10 min, followed202
by 3 min  of isocratic ﬂow proﬁle. The injection volume was  100 l.203
For the analysis of the samples, freshly prepared calibration curves204
were used (R2 ≥ 0.998) and quality controls were run after every205
10–20 samples to ensure accuracy of the method throughout the206
whole sequence.207
2.2.10. Data analysis208
Comparison of two data sets was performed by using unpaired209
Student’s t-test (two tailed). p ≤ 0.05 was considered as signiﬁcantly210
different.211
3. Results212
3.1. Permeation rate213
Aqueous dispersions (in HBSS++) of the ASD F1 (composition214
Table 1) were investigated in terms of the permeation rate of ABT-215
102 across the cell monolayer (Fig. 1). The obtained permeation216
rate values were compared to these of dispersions of crystalline217
ABT-102 in HBSS++, published recently by Frank et al. (2012).218
The dispersion of F1 in HBBS++ yielded signiﬁcantly higher ABT-219
102 permeation rates than crystalline ABT-102. Furthermore, there220
was no signiﬁcant difference observed when FaSSIF was used as221
dispersion medium of F1 instead of HBSS++ (Fig. 1). The ﬂux of222
crystalline ABT-102, dispersed in FaSSIF, was investigated in a pre-223
vious study and found to be not signiﬁcantly different from the ﬂux224
Fig. 1. Caco-2 permeation rates: Normalized ﬂux (divided by area of ﬁlter surface)
of  dispersions of ABT-102 crystals in HBSS++ (n = 5; mean ± SD) and of dispersions
of  the ASD F1 (n = 8; mean ± SD) in HBSS++ and FaSSIF. * Signiﬁcance calculated by
unpaired Student’s t-test (p ≤ 0.05).
of the ABT-102 crystals dispersed in HBSS++, despite the up to 40 225
times increased apparent solubility (Frank et al., 2012). 226
In order to investigate if the observed enhanced permeation 227
rate in the case of the ASD was due to the interaction(s) of excip- 228
ient(s) with the Caco-2-barrier, various control-experiments were 229
performed: 230
The AlamarBlue© assay was  used to assess cytotoxicity of F1 as 231
well as the permeability of carboxyﬂuorescein (CF) to determine 232
if F1 had a deleterious effect on the membrane’s barrier function 233
(Table 2). In both experiments, HBSS++ was  used as negative control 234
and Triton X-100 (1% solution), well known for its cell damaging 235
effect, as positive control. None of the samples showed a cytotoxic 236
effect. The Papp values of the hydrophilic CF in the presence of the 237
sample dispersions were not signiﬁcantly different in comparison 238
to the negative control. 239
Furthermore, using cellZscope®, it was  possible to monitor the 240
TEER throughout the entire course of incubation. There was an ini- 241
tial drop of the TEER values observed for all sample dispersions (and 242
the negative control), but the TEER increased again to the initial 243
starting value. This drop was probably due to the stress, which the 244
cells experienced because of the aspiration of buffer and addition 245
of the samples. Only in case of the positive control Triton X-100, 246
was the resistance close to zero (Fig. 2). 247
In conclusion, a toxic or damaging effect of the sample disper- 248
sions on the cell monolayer could be ruled out. 249
Tween 80 is known to have a P-gp inhibiting effect and therefore 250
might alter the permeation rate of a P-gp substrate. However, ABT- 251
102 has recently been found to be no substrate of the efﬂux pump 252
P-gp (Frank et al., 2012). P-gp inhibition thus is not likely to be the 253
reason for increased ABT-102 permeation rate from the ASD F1. 254
3.2. Characterization of the solid state 255
ASDs are regarded as promising in terms of enhancing bioavail- 256
ability of poorly soluble drugs under the prerequisite that either a 257
dispersion of the amorphous ABT-102 in the polymer matrix (amor- 258
phous solid dispersion) or a solid solution (molecular dispersion) 259
is generated (Brouwers et al., 2009). Powder X-ray scattering was 260
performed in order to check the presence of drug crystallites in the 261
ASD. The diffractogram in Fig. 3 indicates the absence of crystalline 262
ABT-102 in F1. 263
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Table  2
Inﬂuence of the ASD formulation F1, dispersed in HBSS++ and in FaSSIF, on cell viability and on the integrity of the cell monolayer. (a) Cell viability: AlamarBlue® test;
mean  ± SD (n ≥ 16). (b) Integrity of the cell monolayer: Carboxyﬂuorescein permeability; mean ± SD (n ≥ 4).
(a) AlamarBlue® test (b) Carboxyﬂuorescein permeability
Viability [%] Signiﬁcancea Papp [×10−6 cm/s] Signiﬁcancea
HBSS++ 100.0 ± 3.3 Reference 0.17 ± 0.08 Reference
Formulation F 1 in HBSS++ 101.7 ± 5.9 No 0.15 ± 0.09 No
Formulation F1 in FaSSIF 97.0 ± 5.1 No 0.27 ± 0.07 No
Triton  X-100 1% 2.7 ± 0.1 Yes 11.40 ± 1.80 Yes
a Signiﬁcance calculated by unpaired Student’s t-test (p ≤ 0.05).
Fig. 2. Transepithelial electrical resistance measurement: TEER (%) related to mea-
sured TEER before incubation with sample dispersions on the apical sides (n = 3–5,
mean ± SD). All starting values were >250  cm2. –– F1 in FaSSIF; –– F1 in HBSS++;
–– Triton-X (positive control);  HBSS++ (negative control).
3.3. Apparent and molecular solubility264
We  determined apparent and molecular solubility of ABT-102265
in dispersions of F1 in HBSS++ as well as of F1 in FaSSIF.266
First, apparent solubility was investigated. Non-dissolved mate-267
rial (particles) in the dispersions of the ASD was separated by268
centrifugation. The concentration of ABT-102 in the clear to opales-269
cent supernatant was quantiﬁed. Apparent solubility was found to270
be enhanced up to 10 times in case of the dispersion of F1 in HBSS++,271
in comparison to the crystalline form of ABT-102. Furthermore,272
Fig. 3. Powder X-ray diffractogram: small angle X-ray scattering of the extrudate
formulation F1 (solid; right y-axis) and of the placebo extrudate (F1 without ABT-
102), spiked with crystalline ABT-102 (dotted; left y-axis).
the apparent solubility of the crystalline ABT-102 alone was in the 273
same magnitude as a mixture containing crystalline ABT-102 plus 274
placebo extrudate. FaSSIF as dispersion medium further increased 275
the apparent solubility of ABT-102 in dispersions of F1 (100-fold) 276
in comparison to the crystalline ABT-102 in HBSS++. It has been 277
reported in the literature, that the taurocholate and the lecithin, 278
which are present in FaSSIF, generate micelles that may  enhance 279
the solubility of poorly soluble APIs (Schwebel et al., 2011). 280
Inverse dialysis was performed to determine the concentration 281
of molecularly dissolved ABT-102. The cut-off (3500 Da) was  cho- 282
sen such that only molecularly dissolved ABT-102 could pass, not 283
micellar-bound or nanoparticulate one. Table 3 shows the molec- 284
ular solubility of ABT-102 in dispersions of the ASD F1 and of 285
crystalline ABT-102 in HBSS++ and in FaSSIF. 286
In the case of F1 dispersed in HBSS++, the molecular solubility 287
of ABT-102 was found to be doubled in comparison to the one of 288
crystalline ABT-102 (solubility limit). This indicates that dispers- 289
ing F1 resulted in “true” supersaturation of the ABT-102. Inverse 290
dialysis of a physical mixture, containing placebo extrudate plus 291
crystalline ABT-102, dispersed in HBSS++ did not reveal an increase 292
in the concentrations of molecularly dissolved ABT-102. Obviously, 293
supersaturation is not related to the mere presence of the excipi- 294
ents. Interestingly, the same extent of “true” supersaturation (i.e. 295
enhanced molecular solubility of ABT-102) is observed in FaSSIF as 296
compared to HBSS++. 297
4. Discussion 298
The apparent solubility of the ABT-102 containing ASD (F1) in 299
HBSS++ was ten times higher than that of crystalline ABT-102. In 300
addition, the apparent solubility was  higher in FaSSIF as compared 301
to buffer, most likely due to micellar solubilization (Schwebel et al., 302
2011). This indicates two  different solubility enhancement mech- 303
anisms, one related to the amorphous solid dispersion and one 304
related to FaSSIF. The two effects appear to coexist. The apparent 305
solubility of the physical mixture of the placebo extrudate and ABT- 306
102 crystals was in the same range as the apparent solubility of 307
ABT-102 crystals in HBSS++ alone. Micellar drug solubilization by 308
the three surfactants present in the ASD was  thus ruled out. Fur- 309
thermore, the concentrations of the surfactants in the dispersion of 310
the ASD (at the given concentration) are close to, or well below, the 311
Table 3
Solubility of ABT-102. Apparent solubility: Concentrations of ABT-102 in the super-
natant after centrifugation of the sample dispersions (n = 6–7, mean ± SD). Molecular
solubility: Concentrations of molecularly dissolved ABT-102 in the sample disper-
sions, assessed by inverse dialysis (n = 4–6, mean ± SD).
Apparent solubility [g/ml] Molecular solubility
[g/ml]
F1 in HBSS++ 0.58 ± 0.08 0.15 ± 0.01
F1  in FaSSIF 5.43 ± 0.41 0.16 ± 0.01
ABT-102 in HBSS++ 0.05 ± 0.01 0.09 ± 0.01
ABT-102 in FaSSIF++ 2.11 ± 0.28 0.08 ± 0.01
ABT-102 + placebo
extrudate in HBSS++
0.06 ± 0.01 0.08 ± 0.01
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critical micellar concentrations of these surfactants that are given312
in literature (polysorbate 80: Dawson et al., 1989; sucrose palmi-313
tate: Becerra et al., 2006; poloxamer 188: Cheng et al., 2012). Hence,314
it is assumed that there are no micelles generated.315
Interestingly, molecular solubility was only found increased by316
a factor of two in the dispersions of the ASD, irrespective of the317
dispersion medium (FaSSIF or HBSS++), indicating “true” supersat-318
uration. In contrast, a physical mixture of the placebo extrudate319
with the crystalline ABT-102 did not inﬂuence molecular solubil-320
ity. This led us to the conclusion that the increase in molecular321
solubility is a consequence of the amorphous state of the ABT-102322
in the hot melt extrudate. At the same time this rules out potential323
artifacts caused by surfactants, passing the dialysis membrane and324
generating solubilizing micelles inside the dialysis vials.325
Although it has been repeatedly hypothesized in literature that326
ASDs may  generate supersaturation (Brouwers et al., 2009; Linn327
et al., 2012; Miller et al., 2012), the results presented here are to our328
knowledge the ﬁrst experimental proof that molecular solubility is329
enhanced (“true” supersaturation) in aqueous dispersions of ASDs,330
even in the presence of FaSSIF micelles.331
Previous literature reported apparent solubility data, which332
does not distinguish between molecular solubility and colloidal333
solubilization through micelle- or polymer-association. Neverthe-334
less a reasonable correlation between supersaturation data gained335
this way, and bioavailability enhancement has been found in cases336
where supersaturation is induced/stabilized by mesoporous sil-337
ica and/or polymers: Van Speybroeck et al. (2010b) quantiﬁed338
supersaturation of mesoporous silica formulations combined with339
polymers using 0.45 m pore size membrane ﬁltration, and found340
reasonable correlation with rat bioavailability data. In another341
study, Van Speybroeck et al. (2010a) correlated in vitro release of342
various mesoporous silica formulations (ﬁlter pore size 0.1 m)343
with rat bioavailability data, which showed a good correlation344
between AUCs of the dissolution proﬁles and the plasma curves.345
For surfactant-containing formulations, however, there appear346
to be discrepancies between supersaturation/apparent solubility347
and bioavailability: Do et al. (2011) compared apparent solubility348
(using ﬁltration, pore size 0.45 m)  of various “supersaturating”349
fenoﬁbrate formulations (micellar solubilization), with rat AUC350
and Cmax and concluded that they were in disagreement. A dis-351
solution/permeation system was used by Buch et al. (2010b) to352
evaluate both dissolution and permeation across a Caco-2 cell353
monolayer of 5 “supersaturating formulations”. In their data set,354
fraction dissolved (ﬁltrated 0.2 m)  showed only moderate cor-355
relation with in vitro permeability as well as rat bioavailability.356
Interestingly, Buch et al. (2010a) corrected apparent solubility val-357
ues generated by centrifugation, with fraction permeated through358
10 kDa membranes and found surfactant-dependent correlation359
with human bioavailability. They explained their observation by360
a surfactant-speciﬁc interaction with FaSSIF micelles. Permeation361
from dispersions of ASDs containing surfactants has recently been362
shown to be enhanced as compared to the crystalline API (Kanzer363
et al., 2010). However, apparent solubility or molecular solubility364
was not evaluated at the same time.365
In general, passive permeation of poorly soluble and well per-366
meable drugs should increase with increasing concentrations of367
dissolved drug. More recently, several reports indicated that col-368
loidal solubilized drug may  not be available for permeation (Fischer369
et al., 2011; Frank et al., 2012; Ingels et al., 2004). Therefore, we370
correlated permeation rates with apparent solubilities and molec-371
ular solubilities (Fig. 4). Our data indicate that in this case “true”372
supersaturation appears to correlate with enhanced permeation373
rate, while increase in apparent solubility due to micellar solubi-374
lization appears to have little or no impact on permeation rate. One375
should bear in mind, that due to experimental constraints (long376
equilibration times needed for inverse dialysis), the molecularly377
Fig. 4. Correlation plot: Normalized ﬂux (x-axis) plotted against apparent solubility
(left y-axis; solid symbols) and molecular solubility (right y-axis; hollow symbols).
Quadrangle:  crystals in HBSS++; hexagon: F1 dispersed in FaSSIF; triangle: F1 dis-
persed in HBSS++.
dissolved ABT-102 in our experiments has been quantiﬁed 20 h 378
after dispersing the ASDs, while apparent solubility and perme- 379
ation were determined one hour after dispersing the samples in 380
medium. Since supersaturation is known to be a metastable state 381
(Brouwers et al., 2009) our values may  underestimate the extent of 382
supersaturation. 383
5. Conclusion 384
The examined ASD enhanced in vitro permeation rate of ABT- 385
102 across Caco-2-monolayers as compared to the crystalline 386
drug. Enhanced permeation rate goes in parallel with increased 387
concentration of molecularly dissolved ABT-102. In contrast, an 388
even higher increase in apparent solubility due to micellariza- 389
tion neither affects concentration of molecularly dissolved ABT-102 390
nor permeation rate. To our understanding, the results reported 391
here represent the ﬁrst experimental proof that permeation rate 392
enhancement in aqueous dispersions of ASDs is due to enhanced 393
concentration of molecularly dissolved ABT-102 (“true” supersat- 394
uration) rather than enhanced apparent solubility in the presence 395
of surfactants. 396
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